Univar to buy Quaron Group

Published: 12-Feb-2010
Finance Logistics

Belgian chemical distributor Univar is strengthening its presence in Benelux and France with the acquisition of the Quaron Group for an undisclosed sum.


Belgian chemical distributor Univar is strengthening its presence in Benelux and France with the acquisition of the Quaron Group for an undisclosed sum.

Quaron exports chemical products to more than 30 countries from its main distribution depots in Zwijndrecht (the Netherlands), Tournai/Doornik (Belgium) and Rennes, Montereau, Cestas-Bordeaux, Niort and Lille-Haubourdin (France).

"Quaron is a perfect fit for Univar," said John van Osch, president, Univar EMEA. "Its efficient commodity network complements our industry focused product ranges in Benelux and France, and its site in the Netherlands will create new business and operational opportunities for us."

"The expected synergies will mean even better service to customers," added John Regout, chief executive of Quaron.

The acquisition is subject to regulatory approval by the EU Commission.

Univar operates a network of approximately 170 distribution centres throughout North America, Europe and China.




See more

You may also like

Ingredients

Univar expands agreement with Innophos

Read more
Will distribute Eral-Protek and BCS specialist phosphates in Turkey

Trending Articles

  1. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  2. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  3. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
  4. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Ingredients

Univar expands agreement with Innophos

Will distribute Eral-Protek and BCS specialist phosphates in Turkey
Ingredients

Univar completes acquisition of Basic Chemical Solutions

Mark Byrne joins Univar as chief operating officer
Ingredients

Univar expands Benelux business

Will acquire Quaron business in the region by January 2011
Ingredients

Private equity firm invests in Univar

CD&R acquires 42.5% ownership interest
Finance

Univar opens Cairo office

Strengthens position in the region
Ingredients

Univar to open Dubai office

<p>Univar, a global supplier of chemicals and ingredients, is set to expand its business in the Middle East and Africa by opening a new office in Dubai\'s Jebel Ali Free Zone.</p>
Recruitment

Univar employs general manager to spearhead Middle East and Africa operations
Subscribe now